Resistance to EGFR-Targeted Therapy: A Family Affair

Vlacich, Gregory; Coffey, Robert J.

doi:10.1016/j.ccr.2011.10.006

Cited by 61HER2/EGFR in Cancer ResearchLung Cancer Treatments and MutationsColorectal Cancer Treatments and Studies

Resistance to EGFR-Targeted Therapy: A Family Affair

Open access

Vlacich, Gregory, Coffey, Robert J.·2011·Cancer Cell

DOI 10.1016/j.ccr.2011.10.006PMC PMC3616495

Open this paper in CoChat — free account Open PDF

Abstract

The EGFR-directed antibody cetuximab has proven, albeit modest, clinical benefit as monotherapy in head and neck and colorectal cancers. In a recent study, Yonesaka et al. uncovered a new mechanism of cetuximab resistance mediated by increased ERBB2 signaling via amplification of ERBB2 or increased levels of the ERBB3/ERBB4 ligand heregulin.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.ccr.2011.10.006

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Upregulated receptor tyrosine kinases including ERBB2, MET and IGF-1R activate the PI3K/AKT axis or reactivate the ERK pathway independently of EGFR.
“Upregulated receptor tyrosine kinases (RTKs), including ERBB2, MET and IGF-1R, activate the PI3K/AKT axis or reactivate the ERK pathway independently of EGFR [73–76].”
From Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies (2021) · cites this paper as [74]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496 · see citing works
The Mutational Landscape of Head and Neck Squamous Cell Carcinoma
Stransky, N., Egloff, A. M., Tward, A. D., Kostic, A. D., Cibulskis, K., Sivachenko, A., Kryukov, G. V., Lawrence, M. S., Sougnez, C. L., McKenna, A., et al. (2011) · Science · doi:10.1126/science.1208130 · Cited by 2,500 · see citing works
Expression of Epiregulin and Amphiregulin and K-ras Mutation Status Predict Disease Control in Metastatic Colorectal Cancer Patients Treated With Cetuximab
Khambata-Ford, S., Garrett, C. R., Meropol, N. J., Basik, M., Harbison, C. T., Wu, S., Wong, T. W., Huang, X., Takimoto, C. H., Godwin, A. K., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.5437 · Cited by 1,125 · see citing works
A molecularly annotated platform of patient-derived xenografts (“xenopatients”) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer
Bertotti, A., Migliardi, G., Galimi, F., Sassi, F., Torti, D., Isella, C., Corà, D., Di Nicolantonio, F., Buscarino, M., Petti, C., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0109 · Cited by 939 · see citing works
Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab
Yonesaka, K., Zejnullahu, K., Okamoto, I., Satoh, T., Cappuzzo, F., Souglakos, J., Ercan, D., Rogers, A., Roncalli, M., Takeda, M., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002442 · Cited by 663 · see citing works
Human Breast Cancer Cells Selected for Resistance to Trastuzumab In vivo Overexpress Epidermal Growth Factor Receptor and ErbB Ligands and Remain Dependent on the ErbB Receptor Network
Ritter, C. A., Perez-Torres, M., Rinehart, C., Guix, M., Dugger, T., Engelman, J. A., & Arteaga, C. L. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0701 · Cited by 497 · see citing works
Clinical Usefulness of EGFR Gene Copy Number as a Predictive Marker in Colorectal Cancer Patients Treated with Cetuximab: A Fluorescent In situ Hybridization Study
Personeni, N., Fieuws, S., Piessevaux, H. H., Hertogh, G. D., Schutter, J. D., Biesmans, B., Roock, W. D., Capoen, A., Dêbiec‐Rychter, M., Laethem, J. V., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0449 · Cited by 173 · see citing works
Heregulin is sufficient for the promotion of tumorigenicity and metastasis of breast cancer cells in vivo.
Atlas, E., Cardillo, M., Mehmi, I., Zahedkargaran, H., Tang, C. K., & Lupu, R. (2003) · PubMed · Cited by 113 · see citing works
Dual Kinase Inhibition of EGFR and HER2 Overcomes Resistance to Cetuximab in a Novel In Vivo Model of Acquired Cetuximab Resistance
Quesnelle, K. M., & Grandis, J. R. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0370 · Cited by 91 · see citing works
A Phase I-II Study of Combined Blockade of the ErbB Receptor Network with Trastuzumab and Gefitinib in Patients with HER2 (ErbB2)-Overexpressing Metastatic Breast Cancer
Arteaga, C. L., O’Neill, A., Moulder, S. L., Pins, M., Sparano, J. A., Sledge, G. W., & Davidson, N. E. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0482 · Cited by 79 · see citing works

Flagged first, then by citations

Sorted by citations

Target Binding Properties and Cellular Activity of Afatinib (BIBW 2992), an Irreversible ErbB Family Blocker
Solca, F., Dahl, G., Zoephel, A., Bader, G., Sanderson, M., Klein, C., Kraemer, O., Himmelsbach, F., Haaksma, E., & Adolf, G. R. (2012) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.197756 · Cited by 865 · see citing works
Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies
Zhou, J., Ji, Q., & Li, Q. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02130-2 · Cited by 246 · see citing works
Dual Targeting of EGFR and HER3 with MEHD7945A Overcomes Acquired Resistance to EGFR Inhibitors and Radiation
Huang, S., Li, C., Armstrong, E. A., Peet, C. R., Saker, J., Amler, L. C., Sliwkowski, M. X., & Harari, P. M. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1611 · Cited by 190 · see citing works
Targeting of erbB3 receptor to overcome resistance in cancer treatment
Ma, J., Lyu, H., Huang, J., & Liu, B. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-105 · Cited by 176 · see citing works
HER3 signaling and targeted therapy in cancer
Mishra, R., Patel, H. M., Alanazi, S., Yuan, L., & Garrett, J. T. (2018) · Oncology Reviews · doi:10.4081/oncol.2018.355 · Cited by 175 · see citing works
Targeting CTGF, EGF and PDGF pathways to prevent progression of kidney disease
Kok, H. M., Falke, L. L., Goldschmeding, R., & Nguyen, T. Q. (2014) · Nature Reviews Nephrology · doi:10.1038/nrneph.2014.184 · Cited by 172 · see citing works
Pan-HER, an Antibody Mixture Simultaneously Targeting EGFR, HER2, and HER3, Effectively Overcomes Tumor Heterogeneity and Plasticity
Jacobsen, H. J., Poulsen, T. T., Dahlman, A., Kjær, I., Koefoed, K., Sen, J. W., Weilguny, D., Bjerregaard, B., Andersen, C. R., Horak, I. D., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3312 · Cited by 87 · see citing works
An EGFR/PI3K/AKT axis promotes accumulation of the Rac1-GEF Tiam1 that is critical in EGFR-driven tumorigenesis
Zhu, G.-F., Fan, Z., Ding, M., Zhang, H.-B., Mu, L., Ding, Y., Zhang, Y., Jia, B., Chen, L., Chang, Z., et al. (2015) · Oncogene · doi:10.1038/onc.2015.45 · Cited by 86 · see citing works
A Novel Antibody Engineering Strategy for Making Monovalent Bispecific Heterodimeric IgG Antibodies by Electrostatic Steering Mechanism
Liu, Z., Leng, E. C., Gunasekaran, K., Pentony, M., Shen, M., Howard, M., Stoops, J. D., Manchulenko, K., Razinkov, V. I., Liu, H., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.620260 · Cited by 75 · see citing works
Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab
Napolitano, S., Martini, G., Rinaldi, B., Martinelli, E., Donniacuo, M., Berrino, L., Vitagliano, D., Morgillo, F., Barra, G., De Palma, R., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0020 · Cited by 72 · see citing works
EGFR signaling patterns are regulated by its different ligands
Knudsen, S. L. J., Mac, A. S. W., Henriksen, L., van Deurs, B., & Grøvdal, L. M. (2014) · Growth Factors · doi:10.3109/08977194.2014.952410 · Cited by 70 · see citing works
HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models
Wang, D., Qian, G., Zhang, H., Magliocca, K. R., Nannapaneni, S., Amin, A. R. M. R., Rossi, M., Patel, M. R., El‐Deiry, M. W., Wadsworth, J. T., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0558 · Cited by 68 · see citing works
Combination of Anti-HER3 Antibody MM-121/SAR256212 and Cetuximab Inhibits Tumor Growth in Preclinical Models of Head and Neck Squamous Cell Carcinoma
Jiang, N., Wang, D., Hu, Z., Shin, H. J. C., Qian, G., Rahman, M. A., Zhang, H., Amin, A. R. M. R., Nannapaneni, S., Wang, X., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-1093 · Cited by 60 · see citing works
Emerging Glycolysis Targeting and Drug Discovery from Chinese Medicine in Cancer Therapy
Wang, Z., Wang, N., Chen, J., & Shen, J. (2012) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2012/873175 · Cited by 56 · see citing works
Heregulin and HER3 are prognostic biomarkers in oropharyngeal squamous cell carcinoma
Qian, G., Jiang, N., Wang, D., Newman, S., Kim, S., Chen, Z., García, G., MacBeath, G., Shin, D. M., Khuri, F. R., et al. (2015) · Cancer · doi:10.1002/cncr.29549 · Cited by 54 · see citing works
Preclinical evidence of multiple mechanisms underlying trastuzumab resistance in gastric cancer
Arienti, C., Zanoni, M., Pignatta, S., Río, A. D., Carloni, S., Tebaldi, M., Tedaldi, G., & Tesei, A. (2016) · Oncotarget · doi:10.18632/oncotarget.7575 · Cited by 54 · see citing works
Optimizing Advances in Nanoparticle Delivery for Cancer Immunotherapy
Caster, J. M., Callaghan, C. M., Seyedin, S. N., Henderson, K., Sun, B., & Wang, A. Z. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.07.009 · Cited by 55 · see citing works
Inhibition of <scp>SLC1A</scp>5 sensitizes colorectal cancer to cetuximab
Ma, H., Wu, Z., Peng, J., Li, Y., Huang, H., Liao, Y., Zhou, M., Sun, L., Huang, N., Shi, M., et al. (2018) · International Journal of Cancer · doi:10.1002/ijc.31274 · Cited by 52 · see citing works
Advances in Targeting HER3 as an Anticancer Therapy
Jiang, N., Saba, N. F., & Chen, Z. G. (2012) · Chemotherapy Research and Practice · doi:10.1155/2012/817304 · Cited by 53 · see citing works
γ-Tocotrienol suppresses growth and sensitises human colorectal tumours to capecitabine in a nude mouse xenograft model by down-regulating multiple molecules
Prasad, S., Gupta, S. C., Tyagi, A. K., & Aggarwal, B. B. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.257 · Cited by 50 · see citing works
Role of erbB3 receptors in cancer therapeutic resistance
Lee, Y., Ma, J., Lyu, H., Huang, J., Kim, A., & Liu, B. (2014) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmt150 · Cited by 49 · see citing works
Targeting HER3 using mono- and bispecific antibodies or alternative scaffolds
Malm, M., Frejd, F. Y., Ståhl, S., & Löfblom, J. (2016) · mAbs · doi:10.1080/19420862.2016.1212147 · Cited by 49 · see citing works
ERBB4 promotes the proliferation of gastric cancer cells via the PI3K/Akt signaling pathway
Ji, X., Gong, L., Qian, Z., Song, G., & Liu, J. (2018) · Oncology Reports · doi:10.3892/or.2018.6343 · Cited by 46 · see citing works
Erbin interacts with c‐Cbl and promotes tumourigenesis and tumour growth in colorectal cancer by preventing c‐Cbl‐mediated ubiquitination and down‐regulation of EGFR
Yao, S., Zheng, P., Wu, H., Song, L., Ying, X., Xing, C., Li, Y., Xiao, Z., Zhou, X., Shen, T., et al. (2014) · The Journal of Pathology · doi:10.1002/path.4502 · Cited by 42 · see citing works
Targeting the HER Family with Pan-HER Effectively Overcomes Resistance to Cetuximab
Iida, M., Bahrar, H., Brand, T. M., Pearson, H. E., Coan, J. P., Orbuch, R. A., Flanigan, B. G., Swick, A. D., Prabakaran, P. J., Lantto, J., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0012 · Cited by 41 · see citing works
Systemic Therapy for Metastatic Colorectal Cancer: From Current Standards to Future Molecular Targeted Approaches
Atreya, C. E., Yaeger, R., & Chu, E. (2017) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_175679 · Cited by 35 · see citing works
HER3: Toward the Prognostic Significance, Therapeutic Potential, Current Challenges, and Future Therapeutics in Different Types of Cancer
Majumder, A. (2023) · Cells · doi:10.3390/cells12212517 · Cited by 34 · see citing works
Patritumab or placebo, with cetuximab plus platinum therapy in recurrent or metastatic squamous cell carcinoma of the head and neck: A randomised phase II study
Forster, M. D., Dillon, M. T., Kocsis, J., Remenár, É., Pajkos, G., Rolland, F., Greenberg, J., & Harrington, K. J. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.08.017 · Cited by 32 · see citing works
Pan-HER Inhibitor Augments Radiation Response in Human Lung and Head and Neck Cancer Models
Francis, D. M., Huang, S., Armstrong, E. A., Werner, L. R., Hullett, C. R., Li, C., Morris, Z. S., Swick, A. D., Kragh, M., Lantto, J., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1664 · Cited by 30 · see citing works
HER-3 peptide vaccines/mimics: Combined therapy with IGF-1R, HER-2, and HER-1 peptides induces synergistic antitumor effects against breast and pancreatic cancer cells
Miller, M. J., Foy, K. C., Overholser, J. P., Nahta, R., & Kaumaya, P. T. P. (2014) · OncoImmunology · doi:10.4161/21624011.2014.956012 · Cited by 29 · see citing works
A Conjugate of an Anti‐Epidermal Growth Factor Receptor (EGFR) VHH and a Cell‐Penetrating Peptide Drives Receptor Internalization and Blocks EGFR Activation
van Lith, S. A. M., van den Brand, D., Wallbrecher, R., van Duijnhoven, S. M. J., Brock, R. E., & Leenders, W. P. J. (2017) · ChemBioChem · doi:10.1002/cbic.201700444 · Cited by 28 · see citing works
Prolonged Response to HER2-Directed Therapy in a Patient With HER2-Amplified, Rapidly Progressive Metastatic Colorectal Cancer
Parikh, A. R., Atreya, C. E., Korn, W. M., & Venook, A. P. (2016) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0002 · Cited by 27 · see citing works
Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer
Tomasich, E., Steindl, A., Paiato, C., Hatziioannou, T., Kleinberger, M., Berchtold, L., Puhr, R., Hainfellner, J. A., Müllauer, L., Widhalm, G., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0020 · Cited by 26 · see citing works
Modified Trastuzumab and Cetuximab Mediate Efficient Toxin Delivery While Retaining Antibody-Dependent Cell-Mediated Cytotoxicity in Target Cells
Gilabert‐Oriol, R., Thakur, M., von Mallinckrodt, B., Hug, T., Wiesner, B., Eichhorst, J., Melzig, M. F., Fuchs, H., & Weng, A. (2013) · Molecular Pharmaceutics · doi:10.1021/mp400444q · Cited by 25 · see citing works
Bosutinib Inhibits EGFR Activation in Head and Neck Cancer
Segrelles, C., Contreras, D., Navarro-Palomares, E., Gutiérrez‐Muñoz, C., García‐Escudero, R., Paramio, J. M., & Lorz, C. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19071824 · Cited by 24 · see citing works
Chemotherapy for recurrent/metastatic head and neck cancers
Karabajakian, A., Toussaint, P., Neidhardt, E., Paulus, V., Saintigny, P., & Fayette, J. (2017) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000473 · Cited by 22 · see citing works
ErbBs inhibition by lapatinib blocks tumor growth in an orthotopic model of human testicular germ cell tumor
Juliachs, M., Castillo, W., Vidal, A., Piulats, J. M., del Muro, X. G., Condom, E., Hernández‐Losa, J., Teixidó, C., Pandiella, A., Graupera, M., et al. (2013) · International Journal of Cancer · doi:10.1002/ijc.28009 · Cited by 21 · see citing works
Inhibition of SLC1A5 sensitizes colorectal cancer to cetuximab
Ma, Z., Li, T. X., Fu, W., Lei, C., & Hu, S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-821584-5.00023-7 · Cited by 20 · see citing works
Combinatorial approaches targeting the EGFR family and c-Met in SCCHN
Wang, D., Lu, Y., Nannapaneni, S., Griffith, C. C., Steuer, C. E., Qian, G., Wang, X., Chen, Z., Patel, M. R., El‐Deiry, M. W., et al. (2020) · Oral Oncology · doi:10.1016/j.oraloncology.2020.105074 · Cited by 18 · see citing works
Patritumab with Cetuximab plus Platinum-Containing Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: An Open-Label, Phase Ib Study
Dillon, M. T., Grove, L., Newbold, K. L., Shaw, H., Brown, N. F., Mendell, J., Chen, S., Beckman, R. A., Jennings, A., Ricamara, M., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1539 · Cited by 16 · see citing works
10D1F, an Anti-HER3 Antibody That Uniquely Blocks the Receptor Heterodimerization Interface, Potently Inhibits Tumor Growth Across a Broad Panel of Tumor Models
Thakkar, D., Sancenón, V., Taguiam, M. M., Guan, S., Wu, Z., Ng, E. W.-C., Paszkiewicz, K. H., Ingram, P. J., & Boyd-Kirkup, J. D. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0515 · Cited by 15 · see citing works
Simultaneous targeting of HER family pro-survival signaling with Pan-HER antibody mixture is highly effective in TNBC: a preclinical trial with PDXs
Reddy, T. P., Choi, D. S., Anselme, A. C., Qian, W. P., Chen, W., Lantto, J., Horak, I. D., Kragh, M., Chang, J. C., & Rosato, R. R. (2020) · Breast Cancer Research · doi:10.1186/s13058-020-01280-z · Cited by 14 · see citing works
Appropriate Sequence for Afatinib and Cisplatin Combination Improves Anticancer Activity in Head and Neck Squamous Cell Carcinoma
Longton, E., Schmit, K., Fransolet, M., Clement, F., & Michiels, C. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00432 · Cited by 14 · see citing works
First-in-human trial exploring safety, antitumor activity, and pharmacokinetics of Sym013, a recombinant pan-HER antibody mixture, in advanced epithelial malignancies
Berlin, J. D., Tolcher, A. W., Ding, C., Whisenant, J. G., Horak, I. D., Wood, D. L., Nadler, P. I., Hansen, U. H., Lantto, J., Skartved, N. J. Ø., et al. (2022) · Investigational New Drugs · doi:10.1007/s10637-022-01217-7 · Cited by 11 · see citing works
Anti-HER3 Monoclonal Antibody Inhibits Acquired Trastuzumab-Resistant Gynecologic Cancers
Li, X., Duan, Y., Qiao, C., Zhou, T., Yu, M., Geng, J., Feng, J., Shen, B., Lv, M., & Li, Y. (2015) · Technology in Cancer Research & Treatment · doi:10.1177/1533034615588422 · Cited by 8 · see citing works
Function and mode of action of cytohesins in the epidermal growth factor pathway in colorectal cancer cells
Pan, T., Sun, J., Zhou, J., Fu, Z., Hu, Y., Zheng, S. S., & Zhang, S. (2012) · Oncology Letters · doi:10.3892/ol.2012.1064 · Cited by 7 · see citing works
Molecular Targeting of Growth Factor Receptor Signaling in Radiation Oncology
Huang, S., Rodemann, H. P., & Harari, P. M. (2016) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-662-49651-0_3 · Cited by 6 · see citing works
Differences in genomic profile of high-grade urothelial carcinoma according to tumor location
Park, C. K., & Cho, N. H. (2021) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2021.08.019 · Cited by 5 · see citing works
Integrating imaging, exosome and protein network rewiring information to track early tumour evolution of resistance mechanisms
Wong, F., Coban, O., Weitsman, G. E., & Ng, T. (2017) · Convergent Science Physical Oncology · doi:10.1088/2057-1739/aa5cbd · Cited by 5 · see citing works
Generation and Characterization of Rat Monoclonal Antibodies Against Epidermal Growth Factor Receptor
Osaki, T., Wang, C., Tachibana, T., Azuma, M., Kitamura, M., & Nakanishi, T. (2015) · Monoclonal Antibodies in Immunodiagnosis and Immunotherapy · doi:10.1089/mab.2015.0034 · Cited by 3 · see citing works
Meta-analysis reveals no significant correlation between breast cancer survival and ErbB3 expression
Kim, H. J., Kim, A., Ahn, H. S., Ahn, I. M., Choi, J., & Chang, H. (2015) · Apmis · doi:10.1111/apm.12371 · Cited by 3 · see citing works
NOTCH1 signaling promotes protein stability of HER3 through the AKT pathway in squamous cell carcinoma of head and neck
Wang, Y., Liu, I.-J., Chen, K.-C., & Wu, H. (2021) · Oncogenesis · doi:10.1038/s41389-021-00348-5 · Cited by 2 · see citing works
Neuregulin Signaling in the Tumor Microenvironment
Jia, R., Zhao, H., & Wang, S. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-47189-7_1 · Cited by 1 · see citing works
Development of a platform technology for enhanced endo/lysosomal escape of targeted toxins by structurally specific oleanane saponins
Gilabert‐Oriol, R. (2014) · Universitätsbibliothek der FU Berlin Hochschulschriftenstelle u. Dokumentenserver · doi:10.17169/refubium-7621 · Cited by 2 · see citing works
ERBB3-related gene PBX1 is associated with prognosis in patients with HER2-positive breast cancer
Mo, S., Zhong, H., Dai, W., Li, Y., Qi, B., Li, T., & Cai, Y. (2025) · BMC Genomic Data · doi:10.1186/s12863-024-01292-0 · Cited by 1 · see citing works
Resistance to EGF receptor-targeted monoclonal antibodies in the management of advanced colorectal cancer
Karapetis, C. S., & Price, T. J. (2012) · Colorectal Cancer · doi:10.2217/crc.12.14 · Cited by 1 · see citing works
Growth Factors and Tyrosine Kinase Receptors
Robert, J. (2014) · Springer eBooks · doi:10.1007/978-3-319-14340-8_1 · Cited by 1 · see citing works
[Bacterial expression of 183-227aa region of HER3 extracellular domain I and preparation and identification of its polyclonal antibodies].
Zhu, L., Yuan, P., Zhao, Z., Wang, X., Wang, G., & Liang, Y. (2020) · PubMed Central · doi:10.12122/j.issn.1673-4254.2020.06.06
Pan-HER, an antibody mixture, simultaneously targeting EGFR, HER2, and HER3 effectively overcomes resistance to anti-EGFR antibodies
Li, T. X., Lei, C., & Hu, S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-821584-5.00022-5
Dual targeting of EGFR and HER3 with MEHD7945A overcomes acquired resistance to EGFR inhibitors and radiation
Li, G., & Hu, S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-821584-5.00006-7
Etude de la structure et de l'origine des ADN circulants : application à la mise au point d'un test de détection des mutations KRAS et BRAF dans le cancer colorectal
Mouliere, F. C. (2012) · doi:10.70675/1c5449cez60edz4d7dzaf7cz5eeefac08599

Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab
Yonesaka, K., Zejnullahu, K., Okamoto, I., Satoh, T., Cappuzzo, F., Souglakos, J., Ercan, D., Rogers, A., Roncalli, M., Takeda, M., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002442 · Cited by 663 · see citing works
Cetuximab's tip to become irresistible
Villanueva, M. T. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.145
Targeting ERBB2 overcomes resistance to the anti-EGFR therapeutic antibody cetuximab
Wang, C., Li, T. X., Fu, W., & Hu, S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-821584-5.00031-6 · Cited by 2 · see citing works
Translational Study Shed the Light on ERBB2 (HER2), Playing a Key Role for Acquired Resistance to Cetuximab, Anti-EGFR Antibody
Yonesaka, K. (2012) · Annals of Oncology · doi:10.1016/s0923-7534(20)31944-x
Abstract 4833: Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutics antibody cetuximab
Yonesaka, K., Okamoto, I., Taroh, S., Zejnullahu, K., Nishio, K., Fukuoka, M., Janne, P. A., & Nakagawa, K. (2012) · Cancer Research · doi:10.1158/1538-7445.am2012-4833 · Cited by 4 · see citing works

Authors: Vlacich, G., & Coffey, R. J.
Affiliations: Vanderbilt University (US)
Corresponding author: Coffey, Robert J.
ORCID: Vlacich, Gregory
Coffey, Robert J.
Venue: Cancer Cell
Publisher: Elsevier BV
Published: 2011-10
Volume: 20
Issue: 4
Pages: 423-425
ISSN: 1535-6108 (ISSN-L)
DOI: 10.1016/j.ccr.2011.10.006
PMC: PMC3616495
OpenAlex: W2079847998
Cited by: 61
References: 10
Citations by year: 2025: 1 · 2023: 5 · 2022: 1 · 2021: 3 · 2020: 5 · 2019: 2 · 2018: 6 · 2017: 4 · 2016: 7 · 2015: 9 · 2014: 9 · 2013: 2 · 2012: 7
FWCI: 2.84
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 655 d)
Locations: Cancer Cell (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: National Cancer Institute (P50CA095103, R01CA046413)
Topics: Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
Keywords: cetuximab, anti-EGFR therapy, drug resistance, ERBB2 amplification, neuregulin-1, head and neck cancer, colorectal cancer

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Resistance to EGFR-Targeted Therapy: A Family Affair

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Self-check

Cites

Cited by

Related

Record

About these checks